FCAG
SYRS

First Capital Advisors Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

First Capital Advisors Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$3.54K Buy
+1,123
New +$3.61K ﹤0.01% 703

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

First Capital Advisors Group's SYRS Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2023: 1,123 shares worth $3.54K. The stake represents ﹤0.01% of the portfolio and ranks #703 among its holdings.

53 funds tracked by Wall St. Rank hold SYRS as of Q2 2023.

  • First Capital Advisors Group held 1,123 shares of Syros Pharmaceuticals, Inc. Common Stock worth $3.54K as of Q2 2023.
  • Syros Pharmaceuticals, Inc. Common Stock was a new First Capital Advisors Group position in Q2 2023.
  • Syros Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #703 holding.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.